Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: GlobeNewswire
SAN DIEGO , Feb. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Jasper Therapeutics, Inc. (NASDAQ: JSPR), KBR, Inc. (NYSE: KBR), LifeMD, Inc. (NASDAQ: LFMD), and Lineage, Inc. (NASDAQ: LINE) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to the dates listed below may have standing to seek corporate governance reforms focused on executive oversight, the return of funds to the Company, and a court-approved incentive award, at no cost to them. Jasper Therapeutics, Inc. (NASDAQ: JSPR) If you have held Jasper Therapeutics shares continuously since prior to November 30, 2023, you may have standing to seek corporate governance reforms focused on executive oversight at Jasper Therapeutics. To learn more, visit:https://www.johnsonfistel.com/investigations/jasper-therapeutics-inc/or contact Johnson Fistel, P
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Jasper Therapeutics (NASDAQ:JSPR) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous UrticariaGlobeNewswire
- Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical GrowthGlobeNewswire
- Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal InvestigationGlobeNewswire
JSPR
Earnings
- 11/10/25 - Miss
JSPR
Sec Filings
- 1/26/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 1/7/26 - Form 8-K
- JSPR's page on the SEC website